ABSTRACT Background
Interpretation
WGS accurately predicts co-amoxiclav MIC in E. coli, provided mechanisms causing penicillinase hyper-production are considered. Binary interpretations (susceptible/resistant) for co-amoxiclav are poorly reproducible, regardless of phenotyping methodology, and should be reconsidered. Work is needed to evaluate the impact of genotypes/MIC on clinical outcomes.
Funding
National Institutes for Health Research.
RESEARCH IN CONTEXT Evidence before the study
We searched PubMed for publications from inception up until January 1, 2019 using the terms "Escherichia coli", "co-amoxiclav", "drug resistance" "sequencing", and their synonyms, and also reviewed references of retrieved articles and articles identified as "similar articles" by PubMed. Incidence of co-amoxiclav resistance is rising worldwide. Significant discrepancies in characterising co-amoxiclav resistance by different phenotyping methods are observed, raising doubts about the diagnostic validity of drug susceptibility testing. One potential solution is to instead track the genetic determinants of resistance. Mechanisms of resistance to co-amoxiclav, like all beta-lactam/beta-lactamase inhibitor combinations, are diverse and include mechanisms that regulate expression, so previous studies have used a combination of PCR or microarray-based tests. An alternative would be whole-genome sequencing (WGS): for other organisms this has provided a powerful way of identifying resistance and understanding epidemiological associations. Given the complexity of the relationship between genetic variation and resistance, the evidence to date that WGS can reliably predict co-amoxiclav resistance in E. coli, particularly in population representative isolates, is limited.
Added value of this study
Our study investigated whether it was possible to predict co-amoxiclav susceptibility from WGS from unselected E. coli bloodstream infections. By examining the WGS and drug susceptibility testing data from many population-representative clinical isolates, we found that:
• Rather than just relying on presence and absence of gene(s) or mutation(s), additional data from WGS such as relative gene copy number and promoter mutations are essential to identify co-amoxiclav resistance accurately.
• As well as disagreeing with each other, neither of two currently widely used reference phenotypic methods aligned perfectly with the genetic features found. Further, several genetic features had inconsistent effects on phenotype, being found in both resistant and susceptible isolates.
• The effects of some resistance features individually on minimum inhibitory concentrations (MICs) were small, variable and potentially additive. As the distribution of co-amoxiclav MICs spans the breakpoint(s) defining resistance and susceptibility, these changes substantially affect reproducibility and interpretation.
Implications of all available evidence
Co-amoxiclav resistance in E. coli is better thought of as quantitative, rather than qualitative, and methods that infer resistance from WGS data should be adapted to identify genetic features associated with incremental, but individually modest, changes to MICs. While our results are promising, our efforts to validate our WGSbased approach against "gold-standard" culture-based methods have instead uncovered broader issues of reproducibility. The current paradigm enforces a "resistant" vs "susceptible" dichotomy. In reality, resistance is a continuum built up by many individual features inevitably resulting in poor reproducibility and suboptimal concordance. This was seen in our study, with different culture-based methods frequently failing to agree with one another, and repeated measurements often altering the resistance classification of the sample. Analogously, the binary susceptible/resistant classification derived from our genetics-based predictions failed to fully agree with either culture-based method. Given the variability and complexity in both the underlying mechanisms and resulting phenotype, a more transparent approach considering background genetic features, expression levels of betalactamases, MIC values and clinical syndrome, is likely needed to guide management decisions.
INTRODUCTION
Rising co-amoxiclav resistance in E. coli is perceived as a major healthcare problem, with increasing frequency of resistant bloodstream infections (BSI) 1 threatening coamoxiclav's utility and status as the most commonly used antibiotic in Europe. 2 Consequently, many hospitals are considering broadening their first-line empiric antibiotics for common infections. However, there is significant uncertainty created by observed differences in the categorization of clinical samples by the two main assays for co-amoxiclav susceptibility. 3 These differences are so large that increasing co-amoxiclav resistance was suggested to be primarily due to laboratories switching from US Clinical Laboratory Standards Institute (CLSI) to European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines. 4 Recent work, 5 however, suggests that changes in laboratory protocols are unlikely to account for the majority of the increase in resistance. Only one study has investigated whether there are underlying genetic causes for the ongoing rise in co-amoxiclav resistance, 6 but found no evidence of clonal expansion of any specific co-amoxiclav-resistant strains.
However, the genetic epidemiology of co-amoxiclav resistance mechanisms was not investigated.
In addition to its widespread clinical use, co-amoxiclav is a model for betalactam/beta-lactamase inhibitor (BL/BLI) combinations, which are the focus of renewed attention 7 due to the development of novel BL/BLIs with activity against highly drug-resistant organisms. 8 EUCAST has recently published guidelines on setting breakpoints for BL/BLIs, 9 but the inconsistencies seen in testing and clinically interpreting co-amoxiclav resistance threaten to extend to novel BL/BLIs.
One solution is to instead identify the genetic determinants characterizing resistance (resistance genotype) using whole-genome sequencing (WGS). 11 Rather than resistance being associated with the simple presence/absence of specific genes, previous studies have found much co-amoxiclav resistance is likely attributable to mechanisms which increase the effective concentration of beta-lactamases (e.g. 
Evaluating the impact of different phenotypic methods
A subset of 291 isolates were selected using random sampling within strata defined by 
Modelling and predicting MICs
Random effects models (Stata 14.2; StataCorp LP, 2015) were used to investigate the impact of test method and WGS-identified genetic elements on agar dilution log 2
MICs simultaneously, and to create a WGS-based resistance prediction for comparison with phenotype (Supplementary Methods). Elements were categorised depending on frequency (Supplementary Table 2 ). Models included method-specific random effects for each isolate and testing batch, and method-specific (heteroskedastic) errors. All genetic element categories were included a priori, but the most predictive effects of each (including presence/absence of genes and/or promoter mutations and/or gene dosage) was selected using the Akaike Information Criterion (AIC) (Supplementary Table 3 ). Lastly, interaction terms between genetic elements (reflecting saturation effects) and with test methodology (reflecting differential impact of the same genetic mechanism depending on the amoxicillin:clavulanate ratio) were included where p<0·05. Final estimates were then used to predict MICs in all nonsubsample isolates which did not contain resistance features not present in the agar 1 3 dilution subsample. Predicted MICs were then compared to routine laboratory phenotypes.
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RESULTS

Routine laboratory phenotypes and co-amoxiclav resistance genotypes
The collection was highly diverse, representing 152 different sequence types (STs).
The most common was ST73 (161,17%) (Figure 1 ), followed by ST131 (124,13%), which had the highest percentage of phenotypically-resistant isolates (N=74,60%) and was the only ST associated with co-amoxiclav resistance (chi-squared p<0·0001
compared with p>0·16 for all other STs).
The most common beta-lactam resistance mechanisms identified were acquired betalactamase genes, bla TEM (N=427,44%), bla CTX-M (N=73,7%), bla OXA (N=62,6%) and Variant bla TEM and ampC promoters considered to be associated with increased expression were identified in 49 (5%) and 20 (2%) isolates respectively (Supplementary Tables 9-10 ). 30 (3%) of isolates potentially had one non-functional porin, of which 21 also contained a beta-lactamase gene; however, no isolate had "functionally lost" both ompC and ompF.
WGS-derived resistance prediction compared with routine phenotyping
Including features affecting beta-lactamase expression (i.e. the 'extended' approach - We therefore investigated two other hypotheses that could explain the low agreement:
(i) variable accuracy of the different phenotypic methods, and (ii) the binary resistant/susceptible classification being too simplistic.
Variability in gold standard agar dilution phenotypes (EUCAST and CLSI based)
261/291 (90%) isolates selected for agar dilution passed quality controls. The stratified random sampling enriching for resistant phenotypes meant that 160/261 (61%) isolates were co-amoxiclav-resistant by routine AST (Supplementary Table 4 ).
All STs with >10 isolates in the main sample were represented, with 52(20%), 43(16%) and 29(11%) isolates being ST131, ST73 and ST69, respectively, as were all resistance gene families in the main sample (Supplementary Figure 4) .
As expected, EUCAST agar dilution (EAD, fixed 2mg/L clavulanate concentration)
classified more isolates as more resistant than CLSI agar dilution (CAD, ratio 2:1 amoxicillin:clavulanate) (log 2 MIC difference=0·84, p<0.0001). They were also in closer agreement with routine AST (Supplementary Figure 5) Figure 4) and the impact of some features on susceptibility varying both between isolates (Supplementary Figure 7) and within isolate repeats (Supplementary Figure 6) . For example, 4/9 isolates with ampC promoter mutations in the agar dilution subset were found both CAD "R" and CAD "I" on repeat testing. 
WGS-derived resistance prediction in peri-breakpoint and non-peri-breakpoint isolates
Impact of individual resistance features on a continuous measure of susceptibility
Independently, all beta-lactamases were associated with increased MICs in multivariable modelling (Supplementary Table 11 , Figure 5 ). The largest effects of beta-lactamase presence/absence were for bla OXA-1 (i.e. blaOXA:2d model term, Supplementary Methods) and members of the 'other' group of beta-lactamases, comprising either inhibitor resistant beta-lactamases (N=15), or those with unknown impact on beta-lactam susceptibility (N=4) (Supplementary Table 2 ). These caused two-three fold and four fold doubling dilution increases in EAD MIC respectively.
While there was at most weak evidence of a presence/absence effect of non-inhibitor resistant bla TEM (blaTEM:2b model term) (CAD p=0·01, EAD p=0·52) or bla SHV (blaSHV:2b model term) (CAD p=0·92, EAD p=0·26), there was stronger evidence of associations with increased copy number for both (i.e. a gene dosage effect). Table 12 ), promoter mutations were associated with increased MICs (p<0·0001). However, there was no clear increase in MIC independently associated with suspected porin loss (p>0·10).
Consistent with unadjusted analyses (Supplementary
0
Of note, when increased copy number effects were included, EAD (EUCAST) testing methodology accentuated increases in MIC caused by genetic resistance features other than for suspected porin loss and blaCTX-M:2be (p heterogeneity ≤0·05). EAD methodology however was also associated with increased between and within sample standard deviation (Supplementary Table 13 ). 
Predictions of MIC in an independent validation set
DISCUSSION
Decisions about broadening recommended empiric antimicrobial regimens from coamoxiclav are currently being made based on potentially unreliable AST data and an incomplete understanding of the genetic causes of co-amoxiclav resistance. Here, we have confirmed that the mechanisms of resistance are multifactorial, resulting from combinations of multi-copy beta-lactamase genes, mutations in resistance geneassociated promoters, and inhibitor resistance (resistance to clavulanic acid inactivation). Further, the individual effects of some of these features on MIC were small, variable and potentially additive, resulting in only minor shifts around clinical breakpoints, potentially explaining inconsistencies on repeated phenotyping for the same isolate and discrepancies between genotypic predictions and phenotypic susceptible/resistant classifications. Finally, the phenotypic testing methodology significantly affected the magnitude of the effect of these resistance features on the MIC. Thus, despite only moderate success in predicting co-amoxiclav resistance category due to phenotypic inconsistencies, a WGS-based approach could predict the MIC to within one doubling dilution (essential agreement) of the observed MIC for 97% of isolates from a population-representative set of E. coli BSI Our study highlights the importance of isolate sampling frame, phenotyping method and breakpoint selection. A previous study of 76 E. coli isolated from cattle 17 which reported high sensitivity and specificity of WGS to predict co-amoxiclav resistance, contained highly-resistant isolates (30% containing bla CMY-2 ), and only attempted to predict CLSI-defined resistance (>32/16 mg/L). In contrast, in our study, similar to other population representative studies of human isolates, 6,13 only a small proportion of co-amoxiclav resistance was due to inhibitor-resistant beta-lactamases, with most of the resistance being due to hyper-production of beta-lactamases. Further, given there is lack of consensus as to which breakpoint and clavulanate concentration should be used to compare genotype with phenotype in co-amoxiclav, we assessed against both commonly used methods (EUCAST, CLSI).
Compared with other studies of BL/BLIs and E. coli causing human infections, less BL/BLI resistance was accounted for by inhibitor resistant beta-lactamases. 18 To identify resistance in our population-representative set of isolates, we found it critical to consider genetic features that alter expression of beta-lactamases. Although the individual effects of some of these features on MICs were small, they were important, because MICs for many isolates were around the breakpoint. Further, given the small size of these effects and effects of testing methodology, isolates could exhibit either susceptible or resistant phenotypes on repeat testing, supporting the concept of an "intermediate" phenotype. Finally, the discrepancies between EUCAST and CLSI phenotypes we observed were similar to previous studies, 3 suggesting that phenotypic interpretation for one of our most commonly used clinical antibiotics remains open to question.
The main study strengths are the unbiased, large, population-representative sampling frame; detailed, replicated, reference-grade phenotyping for a substantial subset of isolates; detailed and complete genotyping; and the statistical modelling. Modelling associations between resistance features and MIC directly allowed us to avoid inferring the phenotype from the genotype using pre-specified rules and account for the effects of multiple features existing in individual isolates.
One limitation was that agar dilution phenotypes were determined for only 261
isolates, resulting in limited representation of some, rarer resistance elements. This meant firstly, that some infrequent features had to be categorized together for modelling, and secondly, we were unable to assess definitively interactions between all features (e.g. combinations of beta-lactamases). Reassuringly, however, the features causing the greatest MIC increases were those traditionally associated with co-amoxiclav resistance 7 , their specific impact being modelled here for the first time.
Another limitation is that many genetic features, e.g. DNA copy number, are proxies for increased expression. While we assessed the independent effects of these proxies This issue is similar in nature to the problem of predicting resistance caused by the novel bla CTX-M we encountered. These issues highlight the need to utilize knowledge about mechanisms of inhibitor resistance as opposed to relying solely on observed data when predicting resistance in isolates with previously unobserved resistance features.
In summary, WGS can identify the causes of co-amoxiclav resistance in E. coli provided the approach is extended to consider the complicated, polygenic, and expression-related nature of this resistance. Further, our method enabled assayspecific MIC predictions from genetic data. With renewed interest in using BL/BLIs to treat highly drug-resistant infections, our study has implications for both clinical practice and research. Given susceptibility phenotypes are highly dependent on the phenotypic method used, they must be interpreted with caution. Further, the assumption that BL/BLI resistance is binary (susceptible/resistant) may be unhelpful as the same underlying resistance feature can be associated with MICs just below or just above the breakpoint. A genetic approach potentially offers a more reliable method to identify and monitor resistance to co-amoxiclav, as well as resistance to other BL/BLI combinations. Ultimately, given inherent uncertainties in phenotyping, future approaches need to incorporate patient outcomes. Association between DNA copy number and co-amoxiclav MIC in isolates with no alternate resistance features. 
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